Zealand Pharma A/S (OTCMKTS:ZLDPF) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) have been assigned an average recommendation of “Moderate Buy” from the eight ratings firms that are covering the stock, Marketbeat reports. Five investment analysts have rated the stock with a hold recommendation and three have assigned a strong buy recommendation to the company.

ZLDPF has been the topic of several recent research reports. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Zealand Pharma A/S in a report on Tuesday, December 16th. William Blair reiterated a “market perform” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th. BTIG Research raised Zealand Pharma A/S to a “strong-buy” rating in a report on Friday, November 28th. Cantor Fitzgerald reissued a “neutral” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th. Finally, BNP Paribas Exane lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, March 6th.

Zealand Pharma A/S Stock Performance

ZLDPF stock opened at $40.99 on Friday. The firm has a 50 day moving average of $60.87 and a two-hundred day moving average of $69.89. Zealand Pharma A/S has a 12 month low of $35.93 and a 12 month high of $86.38. The company has a market capitalization of $2.91 billion, a price-to-earnings ratio of 3.00 and a beta of 0.75. The company has a quick ratio of 14.10, a current ratio of 14.10 and a debt-to-equity ratio of 0.02.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its quarterly earnings results on Thursday, February 19th. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.34) by $0.53. The business had revenue of $10.79 million for the quarter, compared to the consensus estimate of $19.69 million. Zealand Pharma A/S had a net margin of 70.06% and a return on equity of 49.76%. As a group, equities analysts anticipate that Zealand Pharma A/S will post -2.19 EPS for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.